JP2010536386A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010536386A5 JP2010536386A5 JP2010522105A JP2010522105A JP2010536386A5 JP 2010536386 A5 JP2010536386 A5 JP 2010536386A5 JP 2010522105 A JP2010522105 A JP 2010522105A JP 2010522105 A JP2010522105 A JP 2010522105A JP 2010536386 A5 JP2010536386 A5 JP 2010536386A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- receptor
- item
- arginine
- targeting reagent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95793607P | 2007-08-24 | 2007-08-24 | |
| PCT/US2008/074268 WO2009029601A2 (en) | 2007-08-24 | 2008-08-25 | Receptor-targeting reagents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010536386A JP2010536386A (ja) | 2010-12-02 |
| JP2010536386A5 true JP2010536386A5 (enExample) | 2011-10-06 |
Family
ID=40388106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010522105A Pending JP2010536386A (ja) | 2007-08-24 | 2008-08-25 | 受容体標的化試薬 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US9155798B2 (enExample) |
| EP (1) | EP2197909A4 (enExample) |
| JP (1) | JP2010536386A (enExample) |
| CA (1) | CA2697529A1 (enExample) |
| WO (1) | WO2009029601A2 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120100538A1 (en) | 2009-03-24 | 2012-04-26 | Biocept, Inc. | Devices and methods of cell capture and analysis |
| AU2010229924B2 (en) | 2009-03-24 | 2016-07-21 | Plus Therapeutics Inc. | Devices and methods of cell capture and analysis |
| WO2011016031A2 (en) * | 2009-08-03 | 2011-02-10 | Yeda Research And Development Co. Ltd. | Urinary biomarkers for cancer diagnosis |
| WO2012027494A1 (en) * | 2010-08-24 | 2012-03-01 | Regents Of The University Of Minnesota | Bispecific targeting reagents |
| US9428565B2 (en) | 2011-01-31 | 2016-08-30 | The General Hospital Corporation | Treatment and bioluminescent visualization using multimodal TRAIL molecules |
| EP2850093B1 (en) | 2012-01-27 | 2019-01-09 | The Board of Trustees of the Leland Stanford Junior University | Therapeutic il-13 polypeptides |
| EP3473708B1 (en) | 2012-07-24 | 2021-01-27 | The General Hospital Corporation | Oncolytic virus therapy for resistant tumors |
| CN104619334A (zh) | 2012-08-09 | 2015-05-13 | 利兰斯坦福初级大学董事会 | 超级因子和合成因子:具有新的和增强的信号传导活性的经改造细胞因子 |
| WO2014035474A1 (en) | 2012-08-30 | 2014-03-06 | The General Hospital Corporation | Compositions and methods for treating cancer |
| CN103865899B (zh) * | 2012-12-17 | 2016-04-27 | 山西康宝生物制品股份有限公司 | 具有vegfr2/kdr受体特异性的融合毒素及其编码基因与应用 |
| EP3049526B1 (en) * | 2013-09-24 | 2021-02-24 | Medicenna Therapeutics, Inc. | Interleukin-4 receptor-binding fusion proteins and uses thereof |
| WO2016015015A1 (en) * | 2014-07-24 | 2016-01-28 | Baylor College Of Medicine | Non-invasive radiofrequency field treatment for cancer therapy |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| MX389194B (es) | 2015-10-06 | 2025-03-20 | Univ Minnesota | Compuestos terapéuticos y métodos. |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| EP3694558B1 (en) | 2017-10-10 | 2024-04-10 | Medicenna Therapeutics Inc. | Il-4-fusion formulations for treatment of central nervous system (cns) tumors |
| US12590133B2 (en) | 2018-06-01 | 2026-03-31 | The Board Of Trustees Of The Leland Stanford Junior University | IL-13/IL-4 superkines: immune cell targeting constructs and methods of use thereof |
| WO2019239213A2 (en) | 2018-06-01 | 2019-12-19 | Medicenna Therapeutics Inc. | Uses and methods for oncolytic virus targeting of il-4/il-13 and fusions thereof |
| WO2020033398A1 (en) * | 2018-08-06 | 2020-02-13 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for treating atii cell-dependent lung diseases |
| CN112912400B (zh) | 2018-10-19 | 2025-05-30 | 明尼苏达大学董事会 | Nk接合子分子及其使用方法 |
| WO2020219599A1 (en) * | 2019-04-23 | 2020-10-29 | Aurora Oncology | Compositions and methods for treatment of distentable tissues |
| WO2022135441A1 (zh) * | 2020-12-22 | 2022-06-30 | 江苏恒瑞医药股份有限公司 | 抗il-4r抗体或其抗原结合片段的复合物及医药用途 |
| US20240239857A1 (en) * | 2021-05-19 | 2024-07-18 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Il-13ralpha2 targeted immunotoxins and methods of use |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US142539A (en) * | 1873-09-02 | Improvement | ||
| US6086900A (en) * | 1997-03-26 | 2000-07-11 | Board Of Regents, The University Of Texas Systems | Methods and compositions for using membrane-penetrating proteins to carry materials across cell membranes |
| US6034053A (en) | 1998-07-13 | 2000-03-07 | Wayne Hughes Institute | EGF-isoflavone conjugates for the prevention of restenosis |
| DE19839671C2 (de) * | 1998-09-01 | 2000-08-03 | Forschungszentrum Juelich Gmbh | Sensor zur Messung eines Magnetfeldes |
| US6864359B1 (en) * | 1999-02-11 | 2005-03-08 | Xencor | Structure-based screening techniques for drug discovery |
| US20050142539A1 (en) * | 2002-01-14 | 2005-06-30 | William Herman | Targeted ligands |
| WO2004096254A2 (en) | 2003-05-02 | 2004-11-11 | Xpression Antibody Therapeutics, Inc. | Transferrin conjugates for tumor treatment |
-
2008
- 2008-08-25 EP EP08828457.5A patent/EP2197909A4/en not_active Withdrawn
- 2008-08-25 CA CA2697529A patent/CA2697529A1/en not_active Abandoned
- 2008-08-25 JP JP2010522105A patent/JP2010536386A/ja active Pending
- 2008-08-25 US US12/675,081 patent/US9155798B2/en active Active
- 2008-08-25 WO PCT/US2008/074268 patent/WO2009029601A2/en not_active Ceased
-
2015
- 2015-08-31 US US14/840,479 patent/US20160000868A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010536386A5 (enExample) | ||
| US11833120B2 (en) | Binding protein drug conjugates comprising anthracycline derivatives | |
| Holt et al. | Anti-serum albumin domain antibodies for extending the half-lives of short lived drugs | |
| US20230272033A1 (en) | Epha3 and multi-valent targeting of tumors | |
| Doll et al. | Murine analogues of etanercept and of F8-IL10 inhibit the progression of collagen-induced arthritis in the mouse | |
| CA3062962C (en) | Multispecific protein drug and library thereof, preparing method therefor and application thereof | |
| TW201042041A (en) | Improved anti-serum albumin binding variants | |
| CN112566669A (zh) | 生物素修饰二聚体与酞菁染料的缀合物 | |
| CN113226357A (zh) | 双特异性缀合物 | |
| CN119013305A (zh) | 靶向gpc3的单克隆抗体和包含此抗体的抗体药物缀合物 | |
| CN119343378A (zh) | 靶向itga2的抗体和包含此抗体的抗体药物缀合物 | |
| CN101143902B (zh) | 抗HER2单链抗体-力达霉素强化融合蛋白HER2(Fv-LDM) | |
| CN119950755B (zh) | 一种基于靶向p16单链抗体的抗体片段药物偶联物 | |
| CN119613550B (zh) | 非天然氨基酸修饰的抗pd-l1纳米抗体 | |
| CN113214406B (zh) | 一种结合gpc3融合蛋白的制备方法及应用 | |
| JP2025539402A (ja) | 遺伝子操作型インターロイキン１０及びその融合タンパク質 | |
| CN105399832A (zh) | 一种无标签单链型人源双特异性抗体及其用途 | |
| JP2025513582A (ja) | Ｂｃｍａ細胞外ドメインをマーカーとする遺伝子、ポリペプチド、組換え発現ベクター、遺伝子操作された細胞及び当該遺伝子の使用 | |
| CN101243105A (zh) | 用于靶向ifnar2的方法和组合物 | |
| US10925968B2 (en) | Cell internalizing compounds | |
| CN121311503A (zh) | 靶向itga2的抗体、其抗体药物缀合物以及用途 | |
| CN121086076A (zh) | 一种靶向TF和Her2的双特异性抗体偶联药物及其制备方法和应用 | |
| WO2025051070A1 (zh) | 抗Claudin18.2人源化单域抗体 |